Final Prospectus Filed for Resale of 29.86 Million Shares by Selling Stockholders

summarizeSummary

Ovid Therapeutics filed a final prospectus for the resale of 29.86 million shares by selling stockholders from a recent private placement, potentially diluting existing shareholders by 17.25%.

check_boxKey Events

• Final Prospectus for Share Resale

  Ovid Therapeutics filed this 424B3, serving as the final prospectus for the resale of 29,856,031 shares of common stock by selling stockholders.

• Significant Potential Market Overhang

  The shares registered for resale represent approximately 17.25% of the company's outstanding common stock, which could create downward pressure on the stock price as investors monetize their holdings.

• No New Capital for Company

  The company will not receive any proceeds from the sale of these shares by the selling stockholders, as the capital was raised during the initial private placement on March 19, 2026.

• Follows Prior Registration Filing

  This prospectus finalizes the registration process initiated by the S-3 filing on April 21, 2026, which announced the intent to register these shares for resale.

auto_awesomeAnalysis

This 424B3 filing serves as the final prospectus for the resale of 29.86 million shares of common stock by selling stockholders. These shares were acquired in a private placement that closed on March 19, 2026, at a price of $2.01 per share. The company will not receive any proceeds from these resales, which represents a significant potential dilution of approximately 17.25% if all shares are sold. This finalizes the registration process initiated by the S-3 filing on April 21, 2026, and enables the selling stockholders to monetize their investment, potentially creating an overhang on the stock.